Benign Breast Disease Linked to Increased Risk for Breast Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 13, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Dec. 13, 2023 -- The overall risk for breast cancer (BC) is increased for women diagnosed with benign breast disease (BBD) in the percutaneous biopsy era compared with the general population, according to a study published online Dec. 13 in JAMA Surgery.

Mark E. Sherman, M.D., from the Mayo Clinic in Jacksonville, Florida, and colleagues conducted a retrospective cohort study to estimate BC risk associated with BBD in the percutaneous biopsy era irrespective of surgical biopsy using data from BBD biopsy specimens collected from Jan. 1, 2002, to Dec. 31, 2014. Women were followed until censoring, BC diagnosis, or Dec. 31, 2021. Data were included for 4,819 female participants (median age, 51 years).

The researchers found that risk was higher in the BBD cohort than the Iowa Surveillance, Epidemiology, and End Results program (standard incidence ratios [SIRs], 1.95, 1.56, and 3.10 for BC overall, invasive BC, and ductal carcinoma in situ [DCIS], respectively). There was an increase in SIRs seen with increasing BBD severity (1.42, 2.19, and 3.91 for nonproliferative [NP], proliferative disease without atypia [PDWA], and atypical hyperplasia [AH], respectively), which was comparable to surgical cohorts with BBD. Increased risk was also seen with increasing lesion multiplicity (SIRs, 2.40, 3.72, and 5.29 for at least three foci of NP, PDWA, and AH, respectively). Compared with an expected population cumulative incidence of 2.9 percent, 10-year BC cumulative incidence was 4.3, 6.6, and 14.6 percent for NP, PDWA, and AH, respectively.

"Based on these findings, current clinical management of BBD in the percutaneous biopsy era should remain the same, with close surveillance and consideration of preventive therapy for women with AH," the authors write.

One author disclosed financial ties to AstraZeneca.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-14 00:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords